These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 29569409)

  • 1. Serotonergic compounds in panic disorder, obsessive-compulsive disorder and anxious depression: A concise review.
    Den Boer JA; Westenberg HGM
    Hum Psychopharmacol; 1995 Oct; 10 Suppl 3(S3):S173-S183. PubMed ID: 29569409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH; Goa KL
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
    Piccinelli M; Pini S; Bellantuono C; Wilkinson G
    Br J Psychiatry; 1995 Apr; 166(4):424-43. PubMed ID: 7795913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.
    Figgitt DP; McClellan KJ
    Drugs; 2000 Oct; 60(4):925-54. PubMed ID: 11085201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.
    Gunasekara NS; Noble S; Benfield P
    Drugs; 1998 Jan; 55(1):85-120. PubMed ID: 9463792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder.
    McTavish D; Benfield P
    Drugs; 1990 Jan; 39(1):136-53. PubMed ID: 2178909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.
    Goodman WK; Price LH; Delgado PL; Palumbo J; Krystal JH; Nagy LM; Rasmussen SA; Heninger GR; Charney DS
    Arch Gen Psychiatry; 1990 Jun; 47(6):577-85. PubMed ID: 2112374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of antidepressants.
    Kasper S; Fuger J; Möller HJ
    Drugs; 1992; 43 Suppl 2():11-22; discussion 22-3. PubMed ID: 1378369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological dissection of anxiety disorders: the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine.
    den Boer JA; Westenberg HG; De Leeuw AS; van Vliet IM
    Int Clin Psychopharmacol; 1995 Jan; 9 Suppl 4():47-52. PubMed ID: 7622824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine.
    Mundo E; Rouillon F; Figuera ML; Stigler M
    Hum Psychopharmacol; 2001 Aug; 16(6):461-468. PubMed ID: 12404554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory.
    Jenike MA; Hyman S; Baer L; Holland A; Minichiello WE; Buttolph L; Summergrad P; Seymour R; Ricciardi J
    Am J Psychiatry; 1990 Sep; 147(9):1209-15. PubMed ID: 2143637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative examination of a role for serotonin in obsessive compulsive disorder, panic disorder, and anxiety.
    Murphy DL; Pigott TA
    J Clin Psychiatry; 1990 Apr; 51 Suppl():53-8; discussion 59-60. PubMed ID: 2139026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder.
    Dell'Osso B; Allen A; Hollander E
    Expert Opin Pharmacother; 2005 Dec; 6(15):2727-40. PubMed ID: 16316311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Obsessive-compulsive symptoms associated with panic disorder. Predictive factor of a good therapeutic response to fluvoxamine].
    Servant D; Bailly D; Le Seac'h H; Parquet PJ
    Encephale; 1990; 16 Spec No():359-62. PubMed ID: 2120029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine.
    den Boer JA; Westenberg HG; Kamerbeek WD; Verhoeven WM; Kahn RS
    Int Clin Psychopharmacol; 1987 Jan; 2(1):21-32. PubMed ID: 3117876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluvoxamine in the treatment of anxiety disorders.
    Irons J
    Neuropsychiatr Dis Treat; 2005 Dec; 1(4):289-99. PubMed ID: 18568110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of paroxetine in the treatment of obsessive-compulsive disorders.
    Kamijima K; Aoki M
    Expert Rev Neurother; 2006 Jul; 6(7):945-56. PubMed ID: 16831110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An integrated approach to treatment of obsessive compulsive disorder.
    Greist JH
    J Clin Psychiatry; 1992 Apr; 53 Suppl():38-41. PubMed ID: 1532963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of depression with selective serotonin inhibitors: the role of fluvoxamine.
    Pallanti S; Sandner C
    Int J Psychiatry Clin Pract; 2007; 11(3):233-8. PubMed ID: 24941363
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.